U.S. budget impactanalysis of body surface area (BSA)dosing for a rituximab biosimilar vsflat-fixed-dosing for subcutaneous rituximab in non-Hodgkin lymphoma (NHL)and chronic lymphocytic leukemia (CLL).

Stephen J. Thompson,Holly Trautman,Ali McBride,Azhar Choudhry,Elizabeth James

U.S. budget impactanalysis of body surface area (BSA)dosing for a rituximab biosimilar vsflat-fixed-dosing for subcutaneous rituximab in non-Hodgkin lymphoma (NHL)and chronic lymphocytic leukemia (CLL).

2021

Stephen J. Thompson
Holly Trautman
Ali McBride
Azhar Choudhry
Elizabeth James

e18822Background: The first rituximab biosimilar approved in the US, rituximab-abbs, is a CD20-directed monoclonal antibody that is expected to significantly reduce drug acquisition costs. This eco...

Keywords:

Dosing
Oncology
Monoclonal antibody
Medicine
hodgkin lymphoma
Body surface area
Chronic lymphocytic leukemia
Rituximab
Drug
Internal medicine
Biosimilar

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations